DeepMind’s AlphaProteo designs protein binders for seven targets including VEGF-A
See how this story connectsGoogle DeepMind announced AlphaProteo on 5 September 2024, a system that designs new proteins to bind target molecules. It produced binders for seven targets, including VEGF-A and the SARS-CoV-2 spike receptor-binding domain, with 3 to 300 times better binding affinity than the best existing methods, and failed on an eighth, TNFα. Groups at the Francis Crick Institute validated some binders, and DeepMind said external experts would inform a phased approach to sharing the work, and that it was feeding into community efforts such as the Nuclear Threat Initiative’s AI Bio Forum.
Why it matters
Drug and diagnostic researchers saw AI-designed binders confirmed in outside labs, while DeepMind shared the work in phases and fed into NTI’s AI Bio Forum on biosecurity practice.
- When
- 5 Sep 2024
- ID
WTA-N-2024-0028- Where
- United Kingdom
- Who
- Google DeepMind, Francis Crick Institute, Nuclear Threat Initiative
- Topics
- Biology, Drug discovery, Biosecurity
Summary by wheresthe.ai, from Google DeepMind. Checked against the source on 9 Oct 2026.
Source copy: download the page as saved on 18 Oct 2026 (PDF). Also held by the Internet Archive.
Cite this story
WTA-N-2024-0028: “DeepMind’s AlphaProteo designs protein binders for seven targets including VEGF-A.” wheresthe.ai, 5 Sep 2024. https://wheresthe.ai/d/deepmind-alphaproteo-2024-09/ (source: Google DeepMind).
Spotted an error? Email [email protected].